ReviewInternational journal of biological sciences2026
Microbiota-Gut-Kidney Axis and Targeted Therapeutic Strategies in Kidney Diseases.
Review in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping the aging kidney: a bibliometric atlas of cellular senescence and future frontiers since the 20th century.Frontiers in nephrology · 2026Pooled it
- Gut microbiota in high-altitude acclimatization and adaptation: microbiota homeostasis, double-edged roles, and gut-X axis-specific microbiota reconstruction.Science China. Life sciences · 2026Review
- Unveiling the mechanism of metabolites derived from gut microbiota in the treatment of acute kidney injury via network pharmacology and bioinformatics.Bioresources and bioprocessing · 2026Article
- Associations of Inosine with Gut Microbiota, Metabolic Indicators, and Fluid Homeostasis in Kidney-Related Diarrhea.International journal of molecular sciences · 2026Article
- Gut microbiota in health and disease.Molecular biomedicine · 2026Review
- Targeting Uremic Toxins in Chronic Kidney Disease: Current Challenges and Emerging Therapeutic Strategies.Toxins · 2026Review
- Article
- Traditional Chinese Medicine for Diabetic Kidney Disease: Predominantly Preclinical Evidence, Mechanistic Pathways, and Translational Challenges.Drug design, development and therapy · 2026Review
- Cellular senescence of renal tubular epithelial cells in diabetic kidney disease: emerging mechanisms and targeted interventions.Frontiers in cell and developmental biology · 2026Review
- The associations between healthful and unhealthful plant-based dietary patterns and all-cause mortality among older Chinese adults with data-adapted early-stage cardiovascular-kidney-metabolic syndrome (stages 0-2): a prospective cohort study from the CLHLS.Frontiers in nutrition · 2026Article
- CD4Frontiers in cellular and infection microbiology · 2026Article
- Cardiovascular-kidney-metabolic syndrome: novel molecular mechanism and glucagon-like peptide-1-targeting therapy.Frontiers in cell and developmental biology · 2026Review
- Microbiota-targeted interventions in chronic kidney disease: probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and traditional Chinese medicine.Frontiers in cellular and infection microbiology · 2026Review
- Endothelial-to-Mesenchymal Transition in Chronic Kidney Disease: Mechanisms and Therapeutic Targets.Kidney & blood pressure research · 2026Review
- Microbiota-Associated Metabolites as Immunometabolic Regulators of Glomerular Inflammation: Disease-Specific Mechanisms and Therapeutic Opportunities.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota, as a source of profound genetic and metabolic capacity, affects every aspect of human biology including health, development and aging, as well as disease. Studies have demonstrated the crosstalk between the gut microbiota and the kidney, which is directly referred to as the "microbiota-gut-kidney axis". Most gut microbiota metabolites are associated with metabolic, immune, and inflammatory pathways. Disruption of gut microbiota homeostasis in patients with kidney disease contributes to further loss of kidney function, forming a vicious cycle. This discovery may provide a potential avenue of treatment for kidney diseases, creating a new therapeutic paradigm. Moreover, new therapeutic strategies seem to be beneficial for kidney health via the modulation of the gut microbiota. Although these strategies show early beneficial results, their long-term effectiveness and safety require further investigation and confirmation. In this review, we discuss the interactions between the gut microbiota and kidney diseases and explore related therapeutic strategies. A comprehensive understanding of the microbiota-gut-kidney axis will facilitate the development of efficient therapeutic measures for kidney diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.